Will Abecma Receive Approval in Japan by January 2022? Could JNJ / Legend’s Carvykti be Approved by September 2022?
On Monday, December 6, Japan’s Pharmaceutical Affairs and Food Sanitation Council (PAFSC) granted Abecma (BMS’s BCMA CAR-T) a positive opinion (press release, PharmaJapan, Dec 2021). Below, Celltelligence provides insights on Abecma’s potential approval and reimbursement timeline in Japan.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.